[go: up one dir, main page]

CL2019002002A1 - Liposomas hiperestabilizados que mejoran busqueda de células en mitosis. - Google Patents

Liposomas hiperestabilizados que mejoran busqueda de células en mitosis.

Info

Publication number
CL2019002002A1
CL2019002002A1 CL2019002002A CL2019002002A CL2019002002A1 CL 2019002002 A1 CL2019002002 A1 CL 2019002002A1 CL 2019002002 A CL2019002002 A CL 2019002002A CL 2019002002 A CL2019002002 A CL 2019002002A CL 2019002002 A1 CL2019002002 A1 CL 2019002002A1
Authority
CL
Chile
Prior art keywords
liposomes
hyperstabilized
mitosis
cell search
improve cell
Prior art date
Application number
CL2019002002A
Other languages
English (en)
Inventor
Chang Zhi Adrian Ng
Shen-Yi Ian Cheong
Original Assignee
Temasek Life Sciences Laboratory Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Temasek Life Sciences Laboratory Ltd filed Critical Temasek Life Sciences Laboratory Ltd
Publication of CL2019002002A1 publication Critical patent/CL2019002002A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA PRESENTE INVENCIÓN SE RELACIONA CON EL CAMPO DEL TRATAMIENTO DEL CÁNCER. MÁS ESPECÍFICAMENTE, LA INVENCIÓN SE REFIERE A LIPOSOMAS HIPERESTABLES ÚTILES PARA EL TRATAMIENTO DEL CÁNCER Y A MÉTODOS PARA TRATAR UN CÁNCER USANDO LIPOSOMAS HIPERESTABLES.
CL2019002002A 2017-01-18 2019-07-17 Liposomas hiperestabilizados que mejoran busqueda de células en mitosis. CL2019002002A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762447498P 2017-01-18 2017-01-18

Publications (1)

Publication Number Publication Date
CL2019002002A1 true CL2019002002A1 (es) 2020-01-17

Family

ID=62909275

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019002002A CL2019002002A1 (es) 2017-01-18 2019-07-17 Liposomas hiperestabilizados que mejoran busqueda de células en mitosis.

Country Status (18)

Country Link
US (1) US11331272B2 (es)
EP (1) EP3570818B1 (es)
JP (2) JP7232530B2 (es)
KR (1) KR20190122676A (es)
CN (1) CN110381922A (es)
AU (1) AU2018210748B2 (es)
BR (1) BR112019014718A2 (es)
CA (1) CA3050686A1 (es)
CL (1) CL2019002002A1 (es)
CO (1) CO2019008876A2 (es)
IL (1) IL268099B2 (es)
MA (1) MA47319A (es)
MX (1) MX2019008533A (es)
PH (1) PH12019501650A1 (es)
RU (1) RU2765736C2 (es)
SG (2) SG11201906539YA (es)
TW (1) TWI816656B (es)
WO (1) WO2018136002A1 (es)

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0768117B2 (ja) * 1983-05-06 1995-07-26 ベスター・インコーポレイテツド 薬剤放出調整用小胞製剤
CA1338702C (en) 1987-03-05 1996-11-12 Lawrence D. Mayer High drug:lipid formulations of liposomal- antineoplastic agents
US5714163A (en) * 1994-06-27 1998-02-03 Nexstar Pharmaceuticals, Inc. Vinca alkaloid vesicles with enhanced efficacy and tumor targeting properties
US6120800A (en) * 1997-09-25 2000-09-19 Nexstar Pharmaceuticals, Inc. Vinca-alkaloid vesicles with enhanced efficacy and tumor targeting properties
CA2460209A1 (en) * 2001-09-06 2003-04-24 Yechezkel Barenholz A method for preparing liposome formulations with a predefined release profile
CN103948545B (zh) 2004-05-03 2017-10-03 益普生生物制药公司 用于药物输送的脂质体
JP5057362B2 (ja) 2004-11-02 2012-10-24 国立大学法人 東京医科歯科大学 リポソーム及びこれを用いた細胞に対する物質注入方法
CN101209243B (zh) * 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 一种脂质体药物及其制备方法
WO2009114703A2 (en) * 2008-03-12 2009-09-17 Fox Chase Cancer Center Combination therapy for the treatment of cancer
US20090285881A1 (en) * 2008-04-16 2009-11-19 Abbott Laboratories Cationic lipids and uses thereof
US8318817B2 (en) * 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
MY160203A (en) 2009-03-30 2017-02-28 Eisai R&D Man Co Ltd Liposome composition
BRPI1006600B1 (pt) 2009-04-17 2019-10-08 3M Innovative Properties Company Revestimento de proteção contra descarga atmosférica
WO2010124004A2 (en) * 2009-04-22 2010-10-28 Emory University Nanocarrier therapy for treating invasive tumors
WO2010143972A2 (en) * 2009-06-08 2010-12-16 Epitarget As Acoustically sensitive drug delivery particles comprising non-lamellar forming lipids
US20120301537A1 (en) * 2011-05-23 2012-11-29 Delta-Fly Pharma, Inc. LIPOSOME CONTAINING shRNA MOLECULE TARGETING A THYMIDYLATE SYNTHASE AND USE THEREOF
WO2013066903A1 (en) * 2011-10-31 2013-05-10 Mallinckrodt Llc Combinational liposome compositions for cancer therapy
DK2950784T3 (da) * 2013-02-01 2021-07-05 Zoneone Pharma Inc Fjernladning af svagt vandopløselige lægemidler i liposomer
BR112015022415A2 (pt) * 2013-03-13 2017-07-18 Mallinckrodt Llc composições de cisplatina lipossômica para terapia contra câncer
NZ711500A (en) * 2013-03-15 2020-05-29 Taiwan Liposome Co Ltd Engineering a control drug release profile via liposome compositions in both aqueous and non-aqueous compartments
HK1231397A1 (zh) * 2014-01-14 2017-12-22 The Johns Hopkins University 包封修饰的环糊精复合物的脂质体组合物及其应用
EP3131587A4 (en) * 2014-04-14 2017-11-01 Endocyte, Inc. Drug delivery conjugates for treating resistant cancer and for use in combination therapy
US20160175250A1 (en) * 2014-12-23 2016-06-23 Tolmar Inc. Method for Making Liposomes Containing an Active Pharmaceutical Ingredient
SG11201706371VA (en) * 2015-02-13 2017-09-28 Orient Pharma Inc Compositions and methods of tumor treatment utilizing nanoparticles

Also Published As

Publication number Publication date
TWI816656B (zh) 2023-10-01
CO2019008876A2 (es) 2020-01-17
EP3570818A4 (en) 2020-11-18
TW201828925A (zh) 2018-08-16
EP3570818B1 (en) 2023-11-01
CA3050686A1 (en) 2018-07-26
PH12019501650A1 (en) 2020-02-24
EP3570818A1 (en) 2019-11-27
RU2019125724A (ru) 2021-02-19
AU2018210748B2 (en) 2023-09-28
JP2020505451A (ja) 2020-02-20
MA47319A (fr) 2019-11-27
JP7232530B2 (ja) 2023-03-03
WO2018136002A1 (en) 2018-07-26
JP2023002702A (ja) 2023-01-10
IL268099A (en) 2019-09-26
MX2019008533A (es) 2019-12-02
CN110381922A (zh) 2019-10-25
RU2019125724A3 (es) 2021-03-04
US20190358161A1 (en) 2019-11-28
US11331272B2 (en) 2022-05-17
RU2765736C2 (ru) 2022-02-02
SG11201906539YA (en) 2019-08-27
IL268099B2 (en) 2024-05-01
IL268099B1 (en) 2024-01-01
BR112019014718A2 (pt) 2020-03-10
SG10202107836SA (en) 2021-08-30
KR20190122676A (ko) 2019-10-30
AU2018210748A1 (en) 2019-08-29

Similar Documents

Publication Publication Date Title
NI201900019A (es) Inhibidores de procesos metabólicos celulares
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
CO2020013599A2 (es) Piridazinonas como inhibidoras de parp7
CL2019002304A1 (es) Compuestos para el tratamiento del cáncer.
CL2016001082A1 (es) Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
MX394062B (es) Métodos para el tratamiento del cáncer ovárico.
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
CL2017002786A1 (es) Referencia cruzada a solicitudes relacionadas
EA201790737A1 (ru) Комбинированная терапия
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
MX381046B (es) Anticuerpos anti-csf1r e inhibidores de pd-1/pd-l1, y usos de los mismos para el tratamiento de cáncer remisión a las solicitudes relacionadas.
MX2024000348A (es) Mavacamten para su uso en el tratamiento de la cardiomiopatia hipertrofica.
ECSP15026557A (es) Compuestos y sus métodos de empleo
CL2016003350A1 (es) Inhibidores de demetilasa-1 especifica de lisina
EA201890411A1 (ru) Терапевтически активные соединения и способы их применения
CO2019000753A2 (es) Métodos para tratar el cáncer de próstata
MX2020000386A (es) Inhibidores heterociclicos de la cinasa atr.
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
MX2017006015A (es) Composiciones para usar en el tratamiento de cancer renal.
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
MX2018010993A (es) Derivados de icariina e icaritina.
MX395231B (es) Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de hígado graso, y uso de los mismos.
MX2017006019A (es) Apilimod para uso en el tratamiento de melanoma.
MX2017009246A (es) Farmaco de combinacion.